Market Trends of Automated External Defibrillator Industry
Fully Automated External Defibrillators are Expected to Hold a Significant Share in the Market Over the Forecast Period
Fully automated external defibrillators (FAEDs) analyze the heart's rhythm and deliver a defibrillation shock without user intervention if commanded by the device software.
A few examples of FAEDs are the ZOLL AED Plus Fully Automatic and the Lifeline Auto AED. These devices automatically detect a shockable heart rhythm and administer the shock independently, eliminating the need for the rescuer to push a button. They provide real-time feedback on the depth and rate of chest compressions, ensuring the delivery of high-quality cardiopulmonary resuscitation (CPR) during a rescue.
Various research studies have shown the benefits of FAEDs in quick recovery of cardiac complications in patients. For instance, as per the article published in January 2024 in the Annals of Emergency Medicine journal1, the researchers showed that sudden cardiac arrest issues were not even resolved since the widespread public availability of semi-automated external defibrillators (AEDs) and the teaching of nonbreathing cardiopulmonary resuscitation (CPR) procedures. However, the introduction of the prearrest protocol and the at-home use of fully automated external defibrillators in select cardiac patients reduced the arrest-to-shock interval to under 1 minute and may eliminate the need for CPR in some cases. Thus, owing to such advantages offered by the FAEDs over SAEDs, their demand is likely to rise, leading to segment growth over the forecast period.
The importance of timely use of FAEDs is one of the major factors that lead to the recovery of cardiac complications. People accurately utilize FAEDs for this significant reason. For instance, as per the article published in July 2023 in the Healthcare Delivery, Economics, and Global Health Journal2, the researchers demonstrated that early use of fully automated external defibrillators (AEDs) improved outcomes in out-of-hospital cardiac arrest (OHCA) in Great Britain. Thus, considering such advantages offered by FAEDs, they are expected to support the segment growth over the forecast period.
The rising company collaborations, product launches, funding activities, and regulatory approvals are anticipated to drive the segment growth over the forecast period. For instance:
In January 2023, Avive Solutions Inc. received the US Food and Drug Administration (FDA) pre-market approval (PMA) for its Avive AED, a unique automated external defibrillator (AED). Avive Connect AED is designed for easy placement in a variety of locations, optimized for maximum connectivity, and extensively tested for ease of use. Avive simplifies AED monitoring and maintenance for its customers through daily remote monitoring of their fleet of devices using Avive’s REALConnect Platform.
In June 2023, organizations across England were invited to bid for a share of GBP 1 million (USD 1.2 million) of government funding to buy life-saving automated defibrillators for community spaces like town halls, local parks, or post offices. Hence, such funding activities and government support related to AEDs, including FAEDs, are expected to fuel the segment’s growth over the forecast period.
Therefore, owing to the above-mentioned factors, such as the adoption of FAEDs in cardiac arrhythmia management, increased research studies showing the benefits of FAEDs over SAEDs, product launches, and favorable government support, the market is expected to witness notable growth over the forecast period.
North America is Expected to Hold a Major Market Share Over the Forecast Period
The North American automated external defibrillators market is expected to grow during the forecast period due to the high burden and increasing prevalence of cardiovascular diseases, new product launches, and the emerging number of key market players in the region.
The increasing prevalence of cardiovascular diseases such as heart attack, heart failure, and coronary heart disease, among others, is one of the significant factors driving the market growth over the forecast period. For instance, according to the data updated by the Centers for Disease Control and Prevention in May 2023, every 40 seconds, a heart attack occurs in the United States. About 805,000 Americans experience a heart attack each year. Hence, the rising burden of cardiovascular diseases in the coming years will increase the demand for automated external defibrillators, elevating the market growth over the forecast period.
Cardiovascular diseases are one of the common disorders, with an estimated prevalence of 30%–40% in the Canadian population. Owing to the increasing prevalence of cardiovascular diseases such as heart attack, heart failure, hypertensive heart disease, and arrhythmia, the necessity for early treatment is likely to rise, which is expected to bolster the automated external defibrillator market in the country. For instance, according to the July 2022 update by Heart Disease in Canada, about 1 in 12 (or 2.6 million) Canadian adults age 20 and over live with diagnosed heart disease. Considering the country's high number of heart disease cases, the demand for automated external defibrillators is expected to rise, leading to market growth over the forecast period.
Awareness campaigns and government initiatives to promote the importance of automated external defibrillators, which facilitate market growth. For instance, according to the data updated by the Association of State and Territorial Health Officials in February 2023, several states in the United States introduced legislation to require the placement of automated external defibrillators (AEDs) in specific publicly accessible locations, including highway rest areas, county government buildings all public safety vehicles, hotels, urgent care, and retail health clinics.
Key market players are continuously launching innovative products and product approvals from regulatory bodies in the country, which is expected to bolster the demand for automated external defibrillators over the forecast period. For instance, in March 2024, Stryker launched two new products: LIFEPAK CR2 automated external defibrillator (AED) for cardiac care and Evacuation Chair for emergency patient evacuation. The LIFEPAK CR2 is a revolutionary defibrillator designed to empower rescuers to provide high-quality CPR and deliver instant shock during sudden cardiac arrest (SCA) emergencies. In January 2023, Avive Solutions Inc. received the US Food and Drug Administration (FDA) approval for its Avive AED, a unique automated external defibrillator (AED).
Hence, owing to the increase in cardiovascular disease, the strong foothold of key market players, and their continuous involvement in product launches and awareness campaigns by the government to promote the importance of automated external defibrillators, the North American market is expected to witness notable growth over the forecast period.
